Enzolytics Inc (ENZC)

[foxi]

I'm not saying they want to screw commons, just that the Cash and cash equivalents trajectory is sharply downward, assuming the Q2 numbers are accurately given. If ENZC was truly at half a million cash in June, and doesn't cut normal expense categories in Q3 and Q4, it looks like they would need to secure more cash by approximately year's end to keep above zero.

We haven't seen the Q3 numbers yet so maybe they've already obtained the funding they need. One statement from the August 22 news made it sound like they hadn't.

Given the large number of therapeutics being advanced by Enzolytics, the Company is focused on raising the necessary funds for the production and sale in the U.S. and abroad of IPF Immune™, final development of its anti-HIV ITV-1 therapeutic, accelerating the development of multiple monoclonal antibodies for human therapy, and production of animal monoclonal antibodies. The Company’s audit is being finalized, and the Company fully expects to be able to acquire the funding necessary to complete its multiple programs.

https://enzolytics.com/company-news/

Again, it wouldn't be their intent to undermine existing shareholders with something like a R/S and new dilution, but in the interests of keeping the company running barring a financing partner, circumstances could force their hand.

Maybe they can just sell more Series E to private investors.

Thanks for your input!


.